Doug Drysdale—The Market for Treating Depression & Addiction with Psychedelics EP26
700 million people are affected by mental illness, addiction or eating disorders. And mushrooms can help.
Not the kind you might find at a Grateful Dead concert but the medicinal mushroom molecule of psilocybin.
Doug Drysdale is the CEO of Cybin, a biotechnology company working to advance psychedelic pharmaceutical treatments for mental health issues and addiction.
On this episode of The Wiggin Sessions, Doug joins me to discuss the research around treating major depression with psilocybin and explain how his team is making classical psychedelics more accessible.
Doug describes the size of the market for treating depression, addiction and eating disorders, differentiating Cybin’s work from the psychedelic microdosing trending in Silicon Valley.
Listen in for Doug’s insight on the differences between medicinal marijuana and psilocybin—and learn how investing in Cybin looks to be a win-win for stockholders and anyone living with mental illness.
Key TakeawaysCybin’s work to make classical psychedelic drugs both faster and shorter acting
How Cybin is making psychedelic treatments for depression, addiction and anxiety more accessible
The findings of the Johns Hopkins study on treating major depression with psilocybin
How psilocybin works to make patients more receptive to psychotherapy
Cybin’s innovation in delivering psychedelic therapies (direct contact with bloodstream vs. oral delivery)
The enormous size of the market for treating addiction, depression and eating disorders
Why Cybin is building out an entire care model that includes a psychotherapy program
The differences between medicinal marijuana and psychedelic therapeutics
Why developing psychedelic microdosing treatments is much more challenging than Cybin’s macrodosing treatments
When Cybin’s stock was listed on the NYSE and how that affected the team’s work
How volatility in stock price impacts a biotech company’s ability to finance testing
The potential for consolidation in the biotech space over the next few years
Connect with Doug DrysdaleCybin
Connect with Addison WigginConsilience Financial
Be sure to follow The Wiggin Sessions on your socials. You can find me on—
Facebook @thewigginsessions
Instagram @thewigginsessions
Twitter @WigginSessions
ResourcesPsilocybin Research
‘Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder’ in JAMA Psychiatry
Cybin’s EMBARK Program
Greenbrook TMS
Cybin’s Collaboration with Greenbrook TMS
GW Pharmaceuticals
Create your
podcast in
minutes
It is Free